Miami, FL, April 3, 2024 – Bodor Laboratories Inc. (BLI), a leader in innovative pharmaceutical research and development, is excited to announce the appointment of Dr. Erik T. Bodor as Chief Executive Officer, effective immediately. Dr. E. Bodor, who has significantly contributed to BLI since 2009 as Chief Financial Officer and Vice President of Research, will continue to influence the company’s strategic direction in these roles.

Dr. Nicholas Bodor, the visionary founder, Executive Chairman, and Chief Scientific Officer of BLI, expressed his confidence in the leadership transition. “Erik’s unique blend of scientific acumen and business savvy, underscored by his impressive academic credentials and extensive research experience, makes him the ideal choice to steer BLI towards new frontiers in drug discovery and development.”

Dr. Erik Bodor’s distinguished career is highlighted by dual Bachelor degrees from Emory University, a doctorate in Pharmacology from the University of North Carolina at Chapel Hill, and an MBA from Columbia University. With over two decades of research experience, including a prestigious Alexander von Humboldt research fellowship in Germany, Dr. E. Bodor’s contributions to BLI have been instrumental in forging valuable out-licensing and partnership agreements.

Founded in 2006, Bodor Laboratories has been at the forefront of pharmaceutical innovation, drawing on Dr. Nicholas Bodor’s Retrometabolic Drug Design (RMDD) principles. This innovative approach has yielded several groundbreaking therapies, notably including drugs based on Dr. N. Bodor’s inventions: loteprednol etabonate (ALREX®, LOTEMAX®, ZYLET®, INVELTYS®, EYSUVIS®) and sofpironium bromide (ECCLOCK®).

Sofpironium bromide stands out as a novel “soft anti-cholinergic” developed by BLI, marking a significant advancement in hyperhidrosis treatment. Licensed to Fresh Tracks Therapeutics in 2012 and recently acquired by Botanix Pharmaceuticals, sofpironium bromide (SofdraTM) is on the cusp of FDA approval, anticipated in mid-2024. Already a success in Japan as ECCLOCK®, the drug is poised for further market expansion in South Korea through a partnership with Dong Wha Pharmaceutical.

Bodor Laboratories Inc. is a pioneering pharmaceutical research and development firm focused on leveraging the innovative Retrometabolic Drug Design principles to create effective and safer therapies for patients worldwide. For more detailed information about Bodor Laboratories Inc., our innovative research, and our diverse drug development pipeline, please visit www.bodorlaboratories.com or contact Elvie Guy at [email protected]